Truist keeps Buy rating on Revolution Medicines with $241 price target
Truist Securities maintained its Buy rating on Revolution Medicines with a $241 price target, implying about 35% upside from the October 16 close of $177.96.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Truist Securities maintained its Buy rating on Revolution Medicines shares and kept its price target at $241. According to TradingView, which cites data from Benzinga, the target implies upside of roughly 35.4% from the October 16 close of $177.96.
The analyst note points to peak revenue potential for the company exceeding $16 billion. Much of the optimism rests on daraxonrasib for pancreatic cancer and other RAS-mutant tumors, along with a broad clinical strategy targeting KRAS.
why it matters
For the market, this mainly signals expectations for the company's oncology pipeline. The item concerns a single stock and is fairly routine, yet it reflects individual analysts' confidence in the drug's prospects. Sell-side estimates often shift after clinical trial readouts, so investors may want to watch for new data from the program.
tags
instruments
sources
- Truist Securities maintains Buy rating on Revolution Medicines, $241 price target — TradingView, 19 October 2026 at 13:26 UTC
- Truist Securities maintains Buy rating on Travelers Companies, $435 price target — TradingView, 19 October 2026 at 13:28 UTC
- Truist Securities maintains Buy rating on Toast, $38 price target — TradingView, 19 October 2026 at 13:56 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗